Satellos Bioscience Inc. (TSX:MSCL)
Canada flag Canada · Delayed Price · Currency is CAD
13.95
+0.26 (1.90%)
Jul 24, 2026, 3:55 PM EST

Satellos Bioscience Financials Overview

Millions USD. Fiscal year is Jan - Dec.

Revenue & Profits

Fiscal YearTTMFY 2025FY 2024FY 2023FY 2022FY 2021
Period EndingMar '26 Dec '25 Dec '24 Dec '23 Dec '22 Dec '21
Operating Income
-6.37-26.46-20.4-11.67-6.21-4.62
Net Income
-21.2-24.87-20.63-11.99-8.34-12.27
Earnings Per Share
-0.69-1.70-2.16-1.63-2.83-6.08
EPS Growth
------

Cash & Debt

Fiscal YearCurrentFY 2025FY 2024FY 2023FY 2022FY 2021
Period EndingMar '26 Dec '25 Dec '24 Dec '23 Dec '22 Dec '21
Cash & Investments
69.9127.7148.5529.881.423.85
Total Debt
000000
Net Cash (Debt)
69.9127.7148.5529.881.423.85
Net Cash Growth
69.73%-42.92%62.49%2007.16%-63.21%-
Net Cash Per Share
4.501.905.084.150.481.92

Cash Flow & CapEx

Fiscal YearTTMFY 2025FY 2024FY 2023FY 2022FY 2021
Period EndingMar '26 Dec '25 Dec '24 Dec '23 Dec '22 Dec '21
Operating Cash Flow
-25.82-23.6-18.25-8.74-4.26-3.98
Capital Expenditures
-0.01-0.01-0-0.01-0-0.01
Free Cash Flow
-25.83-23.6-18.26-8.76-4.26-3.99
Free Cash Flow Growth
------